Tumor necrosis factor α blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells-Reference-Cited by-同舟云学术

Tumor necrosis factor α blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells

Published:2010-02 Issue:2 Volume:62 Page:430-440
ISSN:0004-3591
Container-title:Arthritis & Rheumatism
language:en
Short-container-title:Arthritis Rheum

Author:

Ma Hak-Ling,Napierata Lee,Stedman Nancy,Benoit Stephen,Collins Mary,Nickerson-Nutter Cheryl,Young Deborah A.

Publisher

Wiley

Subject

Pharmacology (medical),Immunology,Rheumatology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/art.27203/fullpdf

Reference46 articles.

1. The biology of cachectin/TNF-a primary mediator of the host response;Beutler;Annu Rev Immunol,1989

2. Effect of tumor necrosis factor α on mitogen-activated human B cells;Kehrl;J Exp Med,1987

3. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages: comparison of activating cytokines and evidence for independent production;Ding;J Immunol,1988

4. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts;Dayer;J Exp Med,1985

5. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1;Dinarello;J Exp Med,1986

Cited by 112 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk Factors for the Development of and Outcomes After Diagnosis of Autoimmune Alopecia Areata in Patients with Inflammatory Bowel Diseases;Digestive Diseases and Sciences;2024-07-29

2. The immunopathogenesis of sarcoidosis;Journal of Autoimmunity;2024-05

3. Risk factors for the development of and outcomes after diagnosis of autoimmune alopecia areata in patients with inflammatory bowel diseases;2024-04-10

4. Modulation of Interleukin‐23 Signaling With Guselkumab in Biologic‐Naive Patients Versus Tumor Necrosis Factor Inhibitor–Inadequate Responders With Active Psoriatic Arthritis;Arthritis & Rheumatology;2024-03-04

5. Paradoxe Hautreaktion auf Certolizumab mit Überlappung neutrophiler Dermatosen;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2024-03